{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:07:10Z","timestamp":1791356830439,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jaad.2017.05.043","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T06:24:41Z","timestamp":1503037481000},"page":"675-682.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"title":["Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure"],"prefix":"10.1016","volume":"77","author":[{"given":"Lucy Y.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Strassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggi A.","family":"Refat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.05.043_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.03.022","article-title":"The burden of vitiligo: patient characteristics associated with quality of life","volume":"61","author":"Linthorst Homan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib3","first-page":"45","article-title":"Investigation of factors associated with health-related quality of life and psychological distress in vitiligo","volume":"14","author":"Bonotis","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2017.05.043_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0163-8343(79)90081-1","article-title":"Psychological reaction to chronic skin disorders: a study of patients with vitiligo","volume":"1","author":"Porter","year":"1979","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jaad.2017.05.043_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0781.2006.00222.x","article-title":"Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites","volume":"22","author":"Anbar","year":"2006","journal-title":"Photodermat Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2017.05.043_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2133.1977.tb15180.x","article-title":"Vitiligo: a new classification and therapy","volume":"97","author":"Koga","year":"1977","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jama.293.6.730","article-title":"New insights and new therapies in vitiligo","volume":"293","author":"Grimes","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2017.05.043_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2015.04.008","article-title":"Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients","volume":"73","author":"Bae","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","article-title":"The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo","volume":"76","author":"Mohammad","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/phpp.12277","article-title":"Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis","volume":"33","author":"Li","year":"2017","journal-title":"Photodermat Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2017.05.043_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/138920010791526105","article-title":"Vitiligo: pathogenetic hypotheses and targets for current therapies","volume":"11","author":"Guerra","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jaad.2017.05.043_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/jid.2011.321","article-title":"Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis","volume":"132","author":"Spritz","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib13","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2017.05.043_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","article-title":"HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1","volume":"116","author":"Lang","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib16","first-page":"343","article-title":"Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jaad.2017.05.043_bib17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2017.05.043_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/exd.12264","article-title":"Vitiligo and alopecia areata: apples and oranges?","volume":"22","author":"Harris","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jaad.2015.05.014","article-title":"Confetti-like depigmentation: a potential sign of rapidly progressing vitiligo","volume":"73","author":"Sosa","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.043_bib25","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2017.05.043_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for\u00a0the treatment of severe alopecia areata and variants: A\u00a0study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217317991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217317991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:54Z","timestamp":1759272174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217317991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0190962217317991"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.05.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}